Table 3.

Distribution of characteristics of patients matched with the propensity score according to the initial systemic anti-metastatic therapy.

Characteristics	Initial chemotherapy, N = 186, n (%)	Initial endocrine therapy, N = 186, n (%)	P
Age at diagnostic MBC			0.9170
<65 years	84 (45)	83 (45)
≥65 years	102 (55)	103 (55)
Hormonal status			0.7861
Premenopausal	34 (18)	32 (18)
Postmenopausal	152 (82)	154 (82)
Charlson Comorbidity Index (CCI)			0.7524
CCI = 0	110 (58)	107 (56)
CCI > 0	76 (42)	79 (44)
Primary tumour type			0.7950
Ductal	150 (81)	148 (80)
Lobular	36 (19)	38 (20)
Primary metastatic disease			0.5678
Yes	110 (59)	105 (56)
No	76 (41)	81 (44)
Initial metastatic sites			0.8044
Bone only	60 (32)	62 (33)
Visceral	53 (29)	57 (31)
Multiple	73 (39)	67 (36)
Endocrine resistance			0.1161
Primary	108 (58)	125 (67)
Secondary	28 (15)	27 (15)
Hormone responsive	50 (27)	34 (18)

n number, MBC metastatic breast cancer.